Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Cognitive and motor training for patients with moderate cognitive impairment and mild dementia

https://doi.org/10.14412/2074-2711-2018-4-81-87

Full Text:

Abstract

Objective: to investigate the effectiveness of cognitive and motor training as an additional method to basic therapy in patients with Alzheimer's disease (AD) and vascular cognitive impairment (VCI).

Patients and methods. The investigation enrolled 41 patients (15 women and 26 men; mean age. 73.59+6.3 years), including 32 patients with AD (mean age 74.94+5.15 years) and 9 patients with VCI (mean age, 72.31+4.98 years). Cognitive impairment (CI) corresponded to mild dementia in 15patients (5 women and 10 men; mean age 74.6+2.8years) and to moderate dementia in 29 (10 women and 19 men; mean age 72.1+3.2 years). The patients were randomly assigned to individual, group, and mixed (individual and then group) cognitive training groups. Quantitative scales were used to assess changes in CI and emotional and behavioral disorders after 1.5, 3, and 6 months of therapy.

Results and discussion. During cognitive and motor training, all the groups showed a significant decrease in the severity of CI (p < 0.05), depression, anxiety, and apathy. The effectiveness of the training was further influenced by the severity of concomitant cardiovascular disease, the degree of apathy, adherence to the training, and the early initiation of basic symptomatic therapy.

The greatest positive changes in anxiety and depressive disorders were noted in the patients receiving group cognitive and motor training.

Conclusion. The results of the investigation allow group cognitive and motor training to be recommended as a mainstay in the therapy of patients with CI concurrent with emotional disorders.

About the Authors

A. A. Naumenko
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine

11, Rossolimo St., Build. 1, Moscow 119021



I. S. Preobrazhenskaya
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Irina Sergeevna Preobrazhenskaya - Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine.

11, Rossolimo St., Build. 1, Moscow 119021



References

1. Petersen RC, Stevens JC, Ganguli M, et al. Mild cognitive impairment (an evidence-based review). Neurology. 2001 May 8;56(9):1133-42.

2. Petersen RC. Mild cognitive impairment as a diagnostic entity. JIntern Med. 2004 Sep;256(3): 183-94.

3. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive impairments]. Moscow: Remedium; 2014. 106 p.

4. Parfenov VA, Neverovskii DV. Outpatient management of patients with dyscir-culatory encephalopathy. Nevrologiya, neirop-sikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;7(1):37-42. (In Russ.). doi: 10.14412/2074-2711-2015-1-37-42

5. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002 Oct-Dec;16(4):203-12.

6. Kivipelto M, Helkala EL, Laakso M, et al. Middle life vascular risk factors and Alzheimer’s disease in later life: longitudinal population based study. BMJ. 2001 Jun 16;322(7300):1447-51.

7. Skoog I, Gustafson D. Clinical trials for primary prevention in dementia. In: Rockwood K, Gauthier S, editors. Dementia therapeutic research. London a New York: Taylor a Francis; 2006. P. 189-212.

8. Iqbal K, Winblad B, Nishumura T, et al, editors. Alzheimer's disease: biology, diagnosis and therapeutics. J. Willey and sons; 1997. 831 p.

9. Preobrazhenskaya IS. Poststroke cognitive disorders: causes, clinical manifestations, treatment. Farmateka. 2013;(9):49-53. (In Russ.).

10. Barba R, Castro MD, del Mar Morin M, et al. Prestroke dementia. Cerebrovasc Dis. 2001;11(3):216-24.

11. Hachinski V. Vascular dementia: radical redefinition. In: Carlson LA, Gottfries SG,

12. Winblad B, editors. Vascular dementia: etiology, pathogenesis and clinical aspects. S. Karger; 1994. P. 2-4.

13. Kawashima R. Mental Exercises for Cognitive Function: Clinical Evidence. J Prev Med Public Health. 2013 Jan;46 Suppl 1:S22-7. doi: 10.3961/jpmph.2013.46.S.S22. Epub 2013 Jan 30.

14. Li X, Li D, Li Q, et al. Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. Sci Rep. 2016 Feb 15;6:20873. doi: 10.1038/srep20873.

15. O’Brien J, Ames D, Gustafson L, et al, editors. Cerebrovascular disease, cognitive impairment and dementia. Second edition. Martin Dunitz; 2004.

16. Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to cognitive impairment and dementia: A Statement for healthcare Professionals from the American Heart Association / American Stroke Association. Stroke. 2011 Sep;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.

17. Parfenov VA. Prevention of Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhoso-matika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):8-13. (In Russ.)]. doi: 10.14412/2074-2711-2011-159

18. Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004 Jan;128(1):32-8.

19. Hulette CM. Brain banking in the United States. JNeuropathol Exp Neurol. 2003 Jul; 62(7):715-22.

20. Knopman DS, Parisi JE, Boeve BF, et al. Vascular dementia in a population-based autopsy study. Arch Neurol. 2003 Apr;60(4):569-75.

21. Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging. 2007;2(3):327-35.

22. Kim GH, Lee JH, Seo SW, et al. Hippocampal volume and shape in pure subcortical vascular dementia. Neurobiol Aging. 2015 Jan;36(1):485-91. doi: 10.1016/j.neurobiolag-ing.2014.08.009. Epub 2014 Sep 28.

23. Zakharov VV. Drug therapy in the recovery period of stroke. Farmateka. 2015;(9):80-7. (In Russ.).

24. Butefisch CM. Plasticity in the human cerebral cortex: lessons from the normal brain and from stroke. Neuroscientist. 2004 Apr;10(2):163-73.

25. L0mo T. The discovery of long-term potentiation. Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):617-20.

26. Ziemann U, Muellbacher W, Hallett M, Cohen LG. Modulation of practice-dependent plasticity in human motor cortex. Brain. 2001 Jun;124(Pt 6):1171-81.

27. Zakharov VV. Glutamatergic therapy in the recovery period after ischemic stroke. Effektivnaya farmakoterapiya. Nevrologiya. 2014;(4):6-16. (In Russ.).

28. Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias. Clin Interv Aging. 2009;4:367-77. Epub 2009 Oct 12.

29. Areosa Sastre A, Sheriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154.

30. Orgogozo JM, Rigaud AS, Sto ffler A, et al. Efficacy and Safety of Memantine in Patients with Mild to Moderate Vascular Dementia a Randomized, Placebo-Controlled Trial (MMM 300). Stroke. 2002 Jul;33(7):1834-9.

31. Wilcock G, Mo bius HJ, Sto ffler A; MMM 500 group. A double-blind, placebo-controlled multicenter study of Memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 Nov;17(6):297-305.

32. Levin OS, Yunishchenko NA, Dudarova MA. The effectiveness of akatinol memantine in patients with moderate cognitive disorder. Zhurnal nevrologii ipsikhiatrii im. S.S. Korsakova. 2009;(7):36-42. (In Russ.).

33. Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Mkhitaryan EA. Efficacy of memantin in patients with non-dementia cognitive disorders. Results of a multicenter clinical observations. Nevrologicheskiizhurnal. 2010;15(2): 52-8. (In Russ.).

34. Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD005562. doi: 10.1002/14651858.CD005562.pub2.

35. Martin M, Clare L, Altgassen AM, et al. Cognition-based interventions for healthy older people and people with mild cognitive impairment. Cochrane Database Syst Rev. 2011 Jan 19; (1):CD006220. doi: 10.1002/14651858.CD006220.pub2.

36. Young J, Angevaren M, Rusted J, Tabet N. Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2015 Apr 22;(4):CD005381. doi: 10.1002/14651858.CD005381.pub4.

37. Rodakowski J, Saghafi E, Butters MA, Skidmore ER. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med. 2015 Jun-Oct; 43-44:38-53. doi: 10.1016/j.mam.2015.06.003. Epub 2015 Jun 10.

38. Naumenko AA, Gromova DO, Preobrazhenskaya IS. Cognitive training and rehabilitation of patients with cognitive impairment. Doktor. Ru. 2017;(11):31-8. (In Russ.).

39. Baker LD, Frank LL, Foster-Schubert K, et al. Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial. Arch Neurol. 2010 Jan;67(1):71-9. doi: 10.1001/arch-neurol.2009.307.

40. Schmidt W, Endres M, Dimeo F, Jungehulsing GJ. Train the vessel, gain the brain: physical activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular disease. Cerebrovasc Dis. 2013; 35(4):303-12. doi: 10.1159/000347061. Epub 2013 Apr 10.

41. Bherer L. Cognitive plasticity in older adults: effects of cognitive training and physical exercise. Ann N YAcad Sci. 2015 Mar;1337:1-6. doi: 10.1111/nyas.12682.

42. Bherer L, Kramer AF, Peterson MS, et al. Transfer effects in task-set cost and dual-task cost after dual-task training in older and younger adults: further evidence for cognitive plasticity in attentional control in late adulthood. Exp Aging Res. 2008 Jul-Sep;34(3): 188-219. doi: 10.1080/03610730802070068.

43. Kolb B, Gibb R. Principles of neuroplasticity and behavior. In: Stuss D, Winocur G, Robertson I, editors. Cognitive neurorehabilitation: Evidence and Application. New York: Cambridge University Press; 2008. P. 6-21.

44. Wilson RS, Scherr PA, Schneider JA, et al. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology. 2007 Nov 13; 69(20):1911-20. Epub 2007 Jun 27.

45. Wada M, Noda Y, Shinagawa S, et al. Effect of Education on Alzheimer’s Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer’s Disease: A CrossSectional Study. JAlzheimers Dis. 2018;63(2): 861-869. doi: 10.3233/JAD-171168.

46. Bayer-Carter JL, Green PS, Montine TJ, et al. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol. 2011 Jun;68(6):743-52. doi: 10.1001/archneurol.2011.125.

47. Del Parigi A, Panza F, Capurso C, Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Arch Neurol. 2011 Jun; 68(6):743-52. doi: 10.1001/archneurol.2011.125.

48. Morris MC, Evans DA, Tangney CC, et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology. 2006 Oct 24;67(8):1370-6.

49. Rozzini L, Costardi D, Chilovi BV, et al. Efficacy of Cognitive Rehabilitation in Patients with Mild Cognitive Impairment Treated with Cholinesterase Inhibitors. John Wiley & Sons; 2007. P. 356-60.


For citation:


Naumenko A.A., Preobrazhenskaya I.S. Cognitive and motor training for patients with moderate cognitive impairment and mild dementia. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):81-87. (In Russ.) https://doi.org/10.14412/2074-2711-2018-4-81-87

Views: 562


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)